US20040213744A1 - Topical spray compositions - Google Patents

Topical spray compositions Download PDF

Info

Publication number
US20040213744A1
US20040213744A1 US10/686,517 US68651703A US2004213744A1 US 20040213744 A1 US20040213744 A1 US 20040213744A1 US 68651703 A US68651703 A US 68651703A US 2004213744 A1 US2004213744 A1 US 2004213744A1
Authority
US
United States
Prior art keywords
composition
composition according
medicament
film
canceled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/686,517
Inventor
Amar Lulla
Geena Malhotra
Preeti Raut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
U&I Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U&I Pharmaceuticals Ltd filed Critical U&I Pharmaceuticals Ltd
Priority to US10/686,517 priority Critical patent/US20040213744A1/en
Publication of US20040213744A1 publication Critical patent/US20040213744A1/en
Assigned to CIPLA LIMITED reassignment CIPLA LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: U & I PHARMACEUTICALS, LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances

Definitions

  • This invention relates to compositions for topical application of pharmaceutical compounds. Specifically, the invention relates to topical medicinal spray compositions, their use and films formed upon use. The compositions may be used to treat a variety of disorders.
  • British Patent Specification No. 1,372,721 discloses a container of antiseptic for the topical treatment of bums and scalds, containing a topically acceptable antiseptic active agent against Pseudomonas aeruginosa, a pressuring agent and at least one surfactant admixed with water.
  • the container comprises an outlet, and valve means operable to allow discharge of the contents of the container through the outlet in the form of a foam which is effective in the control of Pseudomonas aeruginosa at the site of a burn or scald.
  • 4,534,958 describes and claims “a sprayable aerosol foam treatment composition which is a liquid in the aerosol container and forms a gel upon application to the skin”.
  • the composition in U.S. Pat. No. 4,534,958 comprises water, propellant, volatile solvent, a polyoxyethylene copolymer whose function is not described, and optionally a burn treatment agent and one or more adjuvants.
  • the composition is used “for treating living skin”.
  • the invention provides advantages not previously realized. Specifically, the invention provides a composition for the topical application of pharmaceutical compounds without causing occlusion problems or skin irritation. Moreover, the inventive compositions remove the need for an adhesive patch. The invention further provides a topically applied composition that may remain as a breathable film on the skin for an extended period of time.
  • This invention relates to a topical spray composition which can be sprayed onto the skin to form a breathable film or patch, which remains stable and in place over a period of days. In this way, a medicament can be delivered transdermally over a period of time. Since the film is non-occlusive, the problem of local skin irritation associated with transdermal patches is substantially reduced.
  • the invention provides a composition for topical application of one or more medicaments, comprising at least one medicament for systemic or topical availability, at least one film former, and one or more vehicles.
  • the composition contains preferably up to about 30% of the at least one medicament, more preferably up to about 10% of the at least one medicament and most preferably up to about 5% of the at least one medicament.
  • the composition may further comprise one or more additional components selected from the group consisting of permeation enhancers, solubilizers, plasticizers, and water soluble additives, including humectants.
  • Medicaments in the composition may be present in a form that is solubilized or suspended. After application, the medicaments may be locally or transdermlly available and may be released from the composition.
  • a wide range of medicaments for human or veterinary use may be used in the composition and the medicament may be present in chiral form.
  • the compositions are preferably in a form suitable for application by spraying from an aerosol or pump spray container.
  • the invention further provides a stable, breathable film formed by applying the inventive compositions.
  • the film is preferably formed over a fixed surface area.
  • the fixed surface area is preferably less than about 50 cm 2 and more preferably from about 10 cm 2 to about 25 cm 2 .
  • Medicaments of the composition may be locally or transdermlly available for release from the film.
  • the invention comprises a method of using the inventive compositions pursuant to which a metered dose of the composition is dispensed onto an intended application site.
  • the intended application site is preferably skin, and the metered dose is preferably applied over a fixed surface area.
  • the fixed surface area is preferably less than about 50 cm 2 and more preferably from about 10 cm 2 to about 25 cm 2 .
  • the metered dose of the composition is preferably dispensed by spraying the composition from a pump or aerosol spray dispenser.
  • the composition forms a stable, breathable film on the intended application site after dispensing.
  • “Breathable film” refers to a film formed on the surface of the skin that does not interfere with perspiration, respiration and other metabolic activities of the skin.
  • “Film-formers” refers to compounds, preferably polymers, that form stable films on a surface when applied.
  • a film is stable if it is resistant to removal by rubbing for an extended period of time.
  • the extended period of time is preferably at least about 24 hours and most preferably from about 1 day to about 5 days.
  • Topical application refers to being applied to a surface such as skin.
  • Topicically active refers to the composition or medicament for topical application which treats predominately the surface on which it is applied.
  • “Percutaneous penetration” or “transdermally available” means that the medicament of the composition is absorbed through skin when applied topically. Typically, although not necessarily, the medicament will then be distributed throughout the body resulting in systemic action as opposed to being only locally active.
  • Permeation Enhancer refers to a component used to enhance the penetration rate of drugs through the skin, preferably by temporarily diminishing the impermeability of the skin. Permeation enhancers have also been called “accelerants” and “sorption promoters.” Examples of permeation enhancers include lipophilic solvents, surfactants, menthol, fatty acid esters and polyhydric alcohols.
  • Plasticizer refers to a component that aids a composition in forming a flexible, adherent film on the skin.
  • plasticizers include citrate esters, dimethyl isosorbide, castor oil, propylene glycol and polyethylene glycol.
  • solubilizer refers to components that aid in the dissolution or dispersement of the drug in the formulation.
  • solubilizers include acrylate and methacrylate ester polymers and copolymers, surfactants, polyhydric alcohols, Vitamin E, Vitamin E TPGS and labrasol.
  • the present invention includes a topical, medicinal spray composition
  • a topical, medicinal spray composition comprising a drug or combination of drugs as a solution or suspension in a vehicle optionally containing a polymer or combination of polymers which, when sprayed on the surface of the skin, forms a film on the skin.
  • the compositions of the invention preferably comprise up to about 30% of at least one medicament (e.g., 0.0001% to about 30%), more preferably up to about 10% of at least one medicament (e.g., 0.0001% to about 10%) and most preferably up to about 5% of at least one medicament (e.g., 0.0001% to about 5%) dissolved or suspended in one or more vehicles which comprise up to 90% of the composition (e.g., 0.0001% to about 90%).
  • the composition may further contain one or more film former, solubilizer, permeation enhancer and plasticizer.
  • the composition may contain one or more of these additives in amounts of up to about 10% film-former (e.g., 0.0001% to about 10%), up to about 10% solubilizer (e.g., 0.0001% to about 10%), up to about 8% permeation enhancer (e.g., 0.0001% to about 8%), and up to about 10% plasticizer (e.g., 0.0001% to about 10%).
  • the inventive composition may be sprayed on a topical site to form a stable, breathable film on the site, from which film the medicaments act locally on the surface or are transdermally available.
  • the composition further comprises up to about 7% (w/w) of one or more water-soluble additives (e.g., 0.0001% to about 7%).
  • the drug or combination of drugs so deposited in the matrix of the film-former may remain solubilized or suspended.
  • the exact formulation of the composition may vary depending on the nature of the particular medicament used (for example, the solubility profile) and the release profile desired.
  • the compositions can be dispensed from any dispenser, preferably a dispenser which provides the composition as a spray, and may be used for systemic action or topical action.
  • the drug from the composition may be released over a period of time or immediately.
  • compositions of the present invention are preferably applied in a metered dose over a predetermined surface area. Accordingly, the present invention may also provide for the administration of the composition by spraying the composition from a dispenser. The invention further provides a method for applying the composition and the resultant film.
  • the composition is dispensed from a pump dispenser or from an aerosol dispenser.
  • the composition additionally comprises from about 10% to 90% of propellant in order to provide a suitable pressure within the aerosol dispenser.
  • propellant is not required for compositions dispensed from a pump dispenser.
  • such compositions may also comprise from about 10% to 90% of a propellant which is liquid at room temperature, for example, trichloromonofluoromethane (P11).
  • the invention also provides a method of preparing a pump dispenser containing the spray composition of the invention comprising mixing the ingredients of the composition with or without liquid propellant and placing the mixed ingredients in a pump dispenser.
  • the invention provides a method of preparing an aerosol dispenser containing the spray composition of the invention comprising mixing the ingredients of the composition without propellant and charging the mixture together with propellant into an aerosol dispenser.
  • the composition is preferably dispensed from the chosen dispenser in a metered dose.
  • the medicament can be any medicinal compound in the salt or base form or a combination of compounds which is stable on mixing with the other ingredients of the composition and effective on topical administration.
  • the medicament is preferably a drug which is an anti-emetic, an anti-anginal, an anti-inflammatory, a steroid, a steroid hormone, a bronchodilator or a drug used to treat osteoporosis.
  • Additional preferred medicaments include drugs used to treat incontinence, antidepressants/anxiolytics, antimigraine agents, agents used in smoking cessation therapy, antidiarrheals, anticholinergics, anticonvulsants, drugs for mood disorders/obsessive compulsive disorder, ACE inhibitors, calcium channel blockers, antihypertensives/diuretics, antiobesity drugs, hormonal peptides and analogues, drugs for benign prostatic hyperplasia/urinary retention and erectile dysfunctions, antiparkinson agents such as dopamine agonists and MAO inhibitors, drugs for sleep disorders and antidiabetic agents.
  • drugs used to treat incontinence include drugs used to treat incontinence, antidepressants/anxiolytics, antimigraine agents, agents used in smoking cessation therapy, antidiarrheals, anticholinergics, anticonvulsants, drugs for mood disorders/obsessive compulsive disorder,
  • Preferred anti-emetic is scopolamine.
  • Preferred anti-anginals include nitroglycerine, clonidine, isosorbide dinitrate, propanolol HCl, timolol maleate, clonazepam and verapamil.
  • Preferred anti-inflammatory drugs include diclofenac sodium, naproxen sodium, ibuprofen, ketoprofen, indomethacin, piroxicam, ketorolac, tromethamine and nimesulide.
  • Preferred steroids include hydrocortisone and esters thereof, dexamethasone, fluocinolone acetonide and betamethasone and salts thereof.
  • Preferred hormonal steroids include estradiol or noethisterone and their pharmaceutically acceptable salts or a combination thereof, testosterone or progesterone.
  • Preferred bronchodilators include salbutamol and salts thereof, bambuterol, salmeterol xinafoate, fluticasone propionate, mometasone furoate, budesonide, beclomethasone dipropionate, sodium cromoglycate and isoprenaline sulphate.
  • Preferred drugs used in case of osteoporosis include alendronic acid, pamidronic acid, etidronic acid and their pharmaceutically acceptable salts.
  • Preferred drugs used to treat incontinence include vasopressin and oxybutynin.
  • Preferred antidepressants/anxiolytics include imipramine, mirtazapine and desipramine.
  • Preferred antimigraine agents include naratriptan, zolmitriptan and sumatriptan.
  • One preferred antidiarrheal is loperamide.
  • One preferred antiulcerant is misoprostol.
  • Preferred anticholinergics include hyoscyamine, atropine and trihexyphenidyl.
  • Preferred anticonvulsants include lorazepam, diazepam and tiagabine.
  • Preferred drugs for antimood disorders/obsessive compulsive disorder include fluoxetine and paroxetine.
  • Preferred ACE inhibitors include lisinopril, trandolapril and captopril.
  • Preferred calcium channel blockers include amlodipine and felodipine.
  • Preferred antihypertensives/diuretics include prazosin and amiloride.
  • Preferred antiobesity drugs include methamphetamine and sibutramine hydrochloride.
  • Preferred hormonal peptides and analogues include GnRH analogues such as nafarelin, leuprolide acetate, insulin and growth hormone and analogues thereof.
  • Preferred drugs for benign prostatic hyperplasia/urinary retention include doxazosin, tamsulosin, terazosin and finasteride.
  • Preferred drugs for erectile dysfunction include alprostadil and sildenafil citrate.
  • Preferred antiparkinson agents include dopamine agonists such as bromocriptine and cabergoline and MAO inhibitors such as selegiline HCl.
  • One preferred agent for sleep disorders is melatonin.
  • Preferred antidiabetic agents include first and second generation sulphonyl ureas such as glimepiride, rosiglitazone, glyburide and glipizide. The chiral forms of all the drugs mentioned above, as well as achiral forms, can be used to make the topical spray composition of the present invention.
  • the film-formers preferably include acrylic polymers or copolymers, including methacrylic polymers and copolymers.
  • Preferred film-formers include a non-ionic copolymer of methyl methacrylate and butyl methacrylate (Plastoid B®), a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®), ammonio methacrylate copolymer type B (Eudragit RS®, USP/NF), ammonio methacrylate copolymer type A (Eudragit RL®, USP/NF), methacrylic acid copolymer type A (Eudragit L100®, USP/NF), methacrylic acid copolymer type B (Eudragit S100® USP/NF), polyvinyl acetate, cellulose acetate, polyvinyl alcohol, povidone, povidone vinyl acetate, hydroxypropyl
  • the breathability of the film is achieved by the absence of any occlusive backing membrane together with the generally hydrophilic properties of the film-forming polymer(s). These polymers can partially dissolve on exposure to moisture (from the skin or air), the dissolution resulting in the formation of a porous film. This porosity can be enhanced by including additional water-soluble additives, such as those detailed below.
  • Preferred solubilizers include a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®, USP/NF); surfactants, for example, sodium lauryl sulphate; polyhydric alcohols, for example, propylene glycol or polyethylene glycol; vitamin E, vitamin E TPGS (tocopheryl polyethylene glycol 1000 succinate) and labrasol; or any two or more of the above in combination.
  • surfactants for example, sodium lauryl sulphate
  • polyhydric alcohols for example, propylene glycol or polyethylene glycol
  • vitamin E vitamin E TPGS (tocopheryl polyethylene glycol 1000 succinate) and labrasol
  • labrasol any two or more of the above in combination.
  • the solubilizer is a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®) in combination with, a non-ionic copolymer of methyl methacrylate and butyl methacrylate (Plastoid B®).
  • the solubilizers serve to dissolve the drug in the chosen vehicle. Many of the solubilizers also enhance percutaneous penetration of drug and/or act as humectants.
  • Preferred plasticizers include triethyl citrate, dimethyl isosorbide, acetyltributyl citrate, castor oil, propylene glycol, and polyethylene glycol, or any two or more of the above in combination.
  • the permeation enhancer is preferably a lipophilic solvent, for example, dimethyl sulfoxide, dimethyl formamide or isopropyl myristate; a surfactant, for example, Tweens or sodium lauryl sulfate; menthol; oleic acid, octyl dimethyl para-amino benzoic acid (Padimate 0); mixed esters of capric and caprylic acid; or a polyhydric alcohol, for example, propylene glycol or diethylene glycol monoethyl ether EP (transcutol); or any two or more of the above in combination.
  • a lipophilic solvent for example, dimethyl sulfoxide, dimethyl formamide or isopropyl myristate
  • a surfactant for example, Tweens or sodium lauryl sulfate
  • menthol oleic acid, octyl dimethyl para-amino benzoic acid (Padimate 0)
  • the vehicle can be water or a non-aqueous solvent.
  • Preferred nonaqueous vehicles include acetone, isopropyl alcohol, methylene chloride, methyl-ethyl-ketone, absolute alcohol, ethyl acetate and trichloromonofluoromethane (P11), methylene dimethyl ether or any two or more of the above in combination.
  • the aqueous or non-aqueous vehicle may additionally comprise (weight/weight of vehicle) up to 20% of one or more humectants.
  • Preferred humectants include polyhydric alcohols and polyvinyl pyrrolidone.
  • Preferred polyhydric alcohols are propylene glycol, butylene glycol, polyethylene glycol, glycerol and sorbitol.
  • the water-soluble additive is preferably propylene glycol, sodium lauryl sulphate, one or more polaxomers, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, cetomacrogol, polyethylene glycol or transcutol, or any two or more of the above in combination.
  • the vehicle When the composition is dispensed as an aerosol, the vehicle partly comprises a propellant in an amount to provide from about 10% to about 90% (w/w) of the composition.
  • the propellant can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure of from about 20 p.s.i.g. to about 130 p.s.i.g.
  • Preferred propellants include hydrocarbons, for example, propane, butane, isobutane, or dimethylether; hydrofluorocarbons and hydrochlorofluorocarbons, for example, dichlorodifluoromethane (P12), trichloromonofluoromethane (P11), dichlorofluoroethane, monochlorodifluoromethane (P22), dichlorotetrafluoroethane (P114), difluoroethane (P152a), tetrafluoroethane (134a), heptafluoropropane (P227b); or compressed gases, for example, nitrogen or carbon dioxide.
  • hydrocarbons for example, propane, butane, isobutane, or dimethylether
  • hydrofluorocarbons and hydrochlorofluorocarbons for example, dichlorodifluoromethane (P12), trichloromonofluoromethane (P11), dichloroflu
  • compositions of the present invention are quick drying, non-occlusive formulations which cause marked enhancement of the skin permeation of the drug both in vitro and in vivo when compared with existing transdermal patches. They offer the advantages of lower skin irritation, greater ease of use, increased dosage flexibility and a simpler method of manufacture when compared to existing transdermal patches.
  • the present compositions are a significant advance over conventional medicinal aerosol compositions, since they permit the application of a medicament by a method whereby no physical contact on the area of application is required, except by the film-forming spray itself.
  • the topical films formed by the present compositions show excellent stability and peelability and can be easily removed from the site of application by washing with water.
  • compositions are generally prepared by mixing the ingredients, without liquefied propellant, at a temperature of from 0° C. to 100° C. and at ambient pressure. If propellant is to be added, the resulting mixture is then charged with the liquefied propellant into an aerosol dispenser to achieve the final composition. Mixing is preferably carried out at a temperature of from 10° C. to 25° C. Alternatively, the mixed composition is placed in a pump dispenser, for example, a metered dose pump, which dispenses the composition typically without liquefied propellant since a pressurized atmosphere is not required. Propellant which is liquid at room temperature may, however, be included in a pump dispenser composition as part of the aqueous vehicle. The composition so prepared is sprayed from the dispenser onto a topical site, at which site it forms a stable, plastic film or patch.
  • the aerosol dispenser is preferably a conventional aerosol can having a conventional metered spray aerosol valve.
  • the pump dispenser is preferably a conventional can or bottle having a conventional metered spray pump.
  • the aerosol dispenser has an all position valve having a shroud that permits spraying when the dispenser is held at any angle. In this way, horizontal bottom surfaces, as well as horizontal top surfaces and vertical surfaces, can be sprayed.
  • the valve actuator can be any actuator which produces a spray and not a foam at the nozzle.
  • a preferred valve actuator is a mechanical breakup actuator, which employs mechanical forces rather than expansion and evaporation of the propellant to produce a spray.
  • a typical mechanical breakup actuator has a conical or cylindrical swirl chamber with an inlet channel oriented perpendicular to the axis thereof.
  • This structure imparts a swirling motion to the aerosol mixture upon discharge.
  • the swirling motion occurs around the axis of the swirl chamber forming a thin conical film of discharged mixture, which breaks into droplets as it leaves the swirl chamber and travels in the direction of the axis thereof.
  • the result is a fine, soft, dispersed spray which can be easily controlled to produce a stable thin film of even thickness completely contacting the application site.
  • the dispenser In dispensing a composition of the invention, the dispenser is typically held about 1 to 2 inches (2.5 to 5 cm) from the application site and produces a film of even thickness.
  • the dispensers used in the present invention are preferably compact units. They can be conveniently used for quick and easy application of a medicament over a large surface area.
  • the composition is preferably applied over a fixed surface area.
  • the fixed surface area is not more than 50 cm 2 , and is more preferably from 10 cm 2 to 25 cm 2 .
  • composition according to the present invention suitable for use in an aerosol dispenser can be prepared as follows:
  • Examples 1 and 2 below represent partly generalized formulas which can be used with any suitable medicament to prepare compositions according to the present invention for use in an aerosol dispenser.
  • compositions for use in an aerosol dispenser are set forth in Examples 3 through 5.
  • composition according to the present invention suitable for use in a pump dispenser, the general method set forth above for an aerosol dispenser can be used, except that it is not necessary to charge the pump dispenser with liquefied propellant to provide a pressurized atmosphere.
  • the mixture itself may contain propellant which is liquid at room temperature as part of the vehicle.
  • Examples 6 through 9 represent partly generalized formulas which can be used with any suitable medicament to prepare compositions according to the present invention for use in a pump dispenser.
  • compositions which can be used in a pump dispenser are set forth in Examples 10 through 12.
  • Eudragit E 100 is a self-adhesive, hydrophilic matrix system. It also acts as a solubilizer for the drug Estradiol.
  • Plastoid B is a film-former. When used together, Eudragit E 100 and Plastoid B give better peelability and water washability than when either is used alone.
  • Acetone is a volatile, quick-drying, non-occlusive vehicle which helps to dispense the contents of the spray over a large surface area.
  • Propylene glycol acts as a humectant to prevent the excessive drying of the application site after application of the medicament. It also acts as a plasticizer for the film formed after application. Propylene glycol additionally acts as a solubilizer for the drug and a permeation enhancer.
  • Sodium lauryl sulfate acts as a solubilizer for the drug
  • Propellant is necessary for developing proper pressure within an aerosol container and for expulsion of the composition when the valve is open. It is also responsible, together with the valve, for dispensing the product as a fine spray.
  • the preferred propellants are very stable compounds and relatively non-toxic, inert and non-flammable.
  • compositions in the above examples were discharged from the dispenser as a fine, soft dispersed spray which could be easily controlled to produce a stable thin film of even thickness on a target surface, for example, a laboratory cover glass.
  • the films have been observed to last for at least 24 hours.
  • concentrations of the film-formers in the composition can be varied as required to obtain a patch which can deliver the drug in a sustained manner for a period of up to 1 to 5 days.
  • the film is easily removable from the application site by water in preparation for reapplication of the film or other treatment.

Abstract

A topical, medicinal spray composition is provided comprising a drug or combination of drugs in a carrier which, when sprayed on a surface, forms a film. The composition comprises at least one medicament, at least one film former and at least one vehicle. The composition of the invention may further comprise at least one permeation enhancer, at least one solubilizer, at least one plasticizer, and at least one water soluble additive. A metered dose of the composition can be sprayed on a topical site to form a stable, breathable film, preferably over a fixed surface area. A wide range of medicaments for human and veterinary use may be present that act locally or transdermally.

Description

  • This application is a continuation of U.S. application Ser. No. 09/503,843, filed Feb. 15, 2000, which claims priority to Indian Patent Application Nos. 382/BOM/99, filed May 20, 1999; 582/BOM/99, filed Aug. 17, 1999; 43/BOM/2000, filed Jan. 13, 2000; and 44/BOM/2000, Jan. 13, 2000, eacjh of which is incorporated herein by reference in its entirety.[0001]
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • This invention relates to compositions for topical application of pharmaceutical compounds. Specifically, the invention relates to topical medicinal spray compositions, their use and films formed upon use. The compositions may be used to treat a variety of disorders. [0003]
  • 2. Background of the Invention [0004]
  • Many delivery systems for the topical application of pharmaceutical compounds are currently available and include lotions, creams, gels, ointments, transdermal patches and sprays. The choice of delivery system usually depends upon the desired pharmacokinetic profile of the drug, for example, whether immediate or sustained release is required. Many of these systems suffer from occlusion problems and may cause skin irritation. For example, many compounds, including hormonal drugs, are conventionally delivered using a transdermal patch. These patches comprise an occlusive backing membrane which often results in local skin irritation. A further disadvantage of transdermal patches is that percutaneous penetration of the drug is often poor. [0005]
  • The problem of skin irritation associated with transdermal patches is not as pronounced when topical spray formulations are used. For example, British Patent Specification No. 1,372,721 discloses a container of antiseptic for the topical treatment of bums and scalds, containing a topically acceptable antiseptic active agent against [0006] Pseudomonas aeruginosa, a pressuring agent and at least one surfactant admixed with water. The container comprises an outlet, and valve means operable to allow discharge of the contents of the container through the outlet in the form of a foam which is effective in the control of Pseudomonas aeruginosa at the site of a burn or scald. U.S. Pat. No. 4,534,958 describes and claims “a sprayable aerosol foam treatment composition which is a liquid in the aerosol container and forms a gel upon application to the skin”. The composition in U.S. Pat. No. 4,534,958 comprises water, propellant, volatile solvent, a polyoxyethylene copolymer whose function is not described, and optionally a burn treatment agent and one or more adjuvants. The composition is used “for treating living skin”.
  • However, conventional topical spray formulations tend to remain at the application site for only a short time. For example, they are easily rubbed off. As a result, the medicament to be absorbed through the skin is only available transiently. By contrast, medicament in a transdermal patch is potentially available for as long as the patch remains in place. [0007]
  • This invention provides advantages not previously realized. Specifically, the invention provides a composition for the topical application of pharmaceutical compounds without causing occlusion problems or skin irritation. Moreover, the inventive compositions remove the need for an adhesive patch. The invention further provides a topically applied composition that may remain as a breathable film on the skin for an extended period of time. [0008]
    • SUMMARY OF THE INVENTION
  • Through this invention, the advantages offered by transdermal patches and topical sprays have been combined, while the disadvantages associated with each have been minimized. This invention relates to a topical spray composition which can be sprayed onto the skin to form a breathable film or patch, which remains stable and in place over a period of days. In this way, a medicament can be delivered transdermally over a period of time. Since the film is non-occlusive, the problem of local skin irritation associated with transdermal patches is substantially reduced. [0009]
  • The invention provides a composition for topical application of one or more medicaments, comprising at least one medicament for systemic or topical availability, at least one film former, and one or more vehicles. The composition contains preferably up to about 30% of the at least one medicament, more preferably up to about 10% of the at least one medicament and most preferably up to about 5% of the at least one medicament. The composition may further comprise one or more additional components selected from the group consisting of permeation enhancers, solubilizers, plasticizers, and water soluble additives, including humectants. Medicaments in the composition may be present in a form that is solubilized or suspended. After application, the medicaments may be locally or transdermlly available and may be released from the composition. A wide range of medicaments for human or veterinary use may be used in the composition and the medicament may be present in chiral form. The compositions are preferably in a form suitable for application by spraying from an aerosol or pump spray container. [0010]
  • The invention further provides a stable, breathable film formed by applying the inventive compositions. The film is preferably formed over a fixed surface area. The fixed surface area is preferably less than about 50 cm[0011] 2 and more preferably from about 10 cm2 to about 25 cm2. Medicaments of the composition may be locally or transdermlly available for release from the film.
  • Moreover, the invention comprises a method of using the inventive compositions pursuant to which a metered dose of the composition is dispensed onto an intended application site. The intended application site is preferably skin, and the metered dose is preferably applied over a fixed surface area. The fixed surface area is preferably less than about 50 cm[0012] 2 and more preferably from about 10 cm2 to about 25 cm2. The metered dose of the composition is preferably dispensed by spraying the composition from a pump or aerosol spray dispenser. In one embodiment, the composition forms a stable, breathable film on the intended application site after dispensing.
  • The above objectives and advantages of the invention are illustrative, and not exhaustive, of those which can be achieved by the invention. The examples presented herein are non-limiting.[0013]
    • DETAILED DESCRIPTION OF THE INVENTION
  • In describing the invention, the following definitions are applicable throughout. [0014]
  • “Breathable film” refers to a film formed on the surface of the skin that does not interfere with perspiration, respiration and other metabolic activities of the skin. [0015]
  • “Film-formers” refers to compounds, preferably polymers, that form stable films on a surface when applied. Within the meaning of the present invention, a film is stable if it is resistant to removal by rubbing for an extended period of time. The extended period of time is preferably at least about 24 hours and most preferably from about 1 day to about 5 days. [0016]
  • “Topical application” refers to being applied to a surface such as skin. [0017]
  • “Topically active” refers to the composition or medicament for topical application which treats predominately the surface on which it is applied. [0018]
  • “Percutaneous penetration” or “transdermally available” means that the medicament of the composition is absorbed through skin when applied topically. Typically, although not necessarily, the medicament will then be distributed throughout the body resulting in systemic action as opposed to being only locally active. [0019]
  • “Permeation Enhancer” refers to a component used to enhance the penetration rate of drugs through the skin, preferably by temporarily diminishing the impermeability of the skin. Permeation enhancers have also been called “accelerants” and “sorption promoters.” Examples of permeation enhancers include lipophilic solvents, surfactants, menthol, fatty acid esters and polyhydric alcohols. [0020]
  • “Plasticizer” refers to a component that aids a composition in forming a flexible, adherent film on the skin. Examples of plasticizers include citrate esters, dimethyl isosorbide, castor oil, propylene glycol and polyethylene glycol. [0021]
  • “Solubilizer” refers to components that aid in the dissolution or dispersement of the drug in the formulation. Examples of solubilizers include acrylate and methacrylate ester polymers and copolymers, surfactants, polyhydric alcohols, Vitamin E, Vitamin E TPGS and labrasol. [0022]
  • The present invention includes a topical, medicinal spray composition comprising a drug or combination of drugs as a solution or suspension in a vehicle optionally containing a polymer or combination of polymers which, when sprayed on the surface of the skin, forms a film on the skin. The compositions of the invention preferably comprise up to about 30% of at least one medicament (e.g., 0.0001% to about 30%), more preferably up to about 10% of at least one medicament (e.g., 0.0001% to about 10%) and most preferably up to about 5% of at least one medicament (e.g., 0.0001% to about 5%) dissolved or suspended in one or more vehicles which comprise up to 90% of the composition (e.g., 0.0001% to about 90%). The composition may further contain one or more film former, solubilizer, permeation enhancer and plasticizer. The composition may contain one or more of these additives in amounts of up to about 10% film-former (e.g., 0.0001% to about 10%), up to about 10% solubilizer (e.g., 0.0001% to about 10%), up to about 8% permeation enhancer (e.g., 0.0001% to about 8%), and up to about 10% plasticizer (e.g., 0.0001% to about 10%). The inventive composition may be sprayed on a topical site to form a stable, breathable film on the site, from which film the medicaments act locally on the surface or are transdermally available. Preferably, the composition further comprises up to about 7% (w/w) of one or more water-soluble additives (e.g., 0.0001% to about 7%). The drug or combination of drugs so deposited in the matrix of the film-former may remain solubilized or suspended. The exact formulation of the composition may vary depending on the nature of the particular medicament used (for example, the solubility profile) and the release profile desired. The compositions can be dispensed from any dispenser, preferably a dispenser which provides the composition as a spray, and may be used for systemic action or topical action. The drug from the composition may be released over a period of time or immediately. [0023]
  • The compositions of the present invention are preferably applied in a metered dose over a predetermined surface area. Accordingly, the present invention may also provide for the administration of the composition by spraying the composition from a dispenser. The invention further provides a method for applying the composition and the resultant film. [0024]
  • Preferably, the composition is dispensed from a pump dispenser or from an aerosol dispenser. In the latter case, the composition additionally comprises from about 10% to 90% of propellant in order to provide a suitable pressure within the aerosol dispenser. Generally, propellant is not required for compositions dispensed from a pump dispenser. However, if desired, such compositions may also comprise from about 10% to 90% of a propellant which is liquid at room temperature, for example, trichloromonofluoromethane (P11). [0025]
  • The invention also provides a method of preparing a pump dispenser containing the spray composition of the invention comprising mixing the ingredients of the composition with or without liquid propellant and placing the mixed ingredients in a pump dispenser. [0026]
  • In addition, the invention provides a method of preparing an aerosol dispenser containing the spray composition of the invention comprising mixing the ingredients of the composition without propellant and charging the mixture together with propellant into an aerosol dispenser. The composition is preferably dispensed from the chosen dispenser in a metered dose. [0027]
  • The medicament can be any medicinal compound in the salt or base form or a combination of compounds which is stable on mixing with the other ingredients of the composition and effective on topical administration. The medicament is preferably a drug which is an anti-emetic, an anti-anginal, an anti-inflammatory, a steroid, a steroid hormone, a bronchodilator or a drug used to treat osteoporosis. Additional preferred medicaments include drugs used to treat incontinence, antidepressants/anxiolytics, antimigraine agents, agents used in smoking cessation therapy, antidiarrheals, anticholinergics, anticonvulsants, drugs for mood disorders/obsessive compulsive disorder, ACE inhibitors, calcium channel blockers, antihypertensives/diuretics, antiobesity drugs, hormonal peptides and analogues, drugs for benign prostatic hyperplasia/urinary retention and erectile dysfunctions, antiparkinson agents such as dopamine agonists and MAO inhibitors, drugs for sleep disorders and antidiabetic agents. [0028]
  • One preferred anti-emetic is scopolamine. Preferred anti-anginals include nitroglycerine, clonidine, isosorbide dinitrate, propanolol HCl, timolol maleate, clonazepam and verapamil. Preferred anti-inflammatory drugs include diclofenac sodium, naproxen sodium, ibuprofen, ketoprofen, indomethacin, piroxicam, ketorolac, tromethamine and nimesulide. Preferred steroids include hydrocortisone and esters thereof, dexamethasone, fluocinolone acetonide and betamethasone and salts thereof. Preferred hormonal steroids include estradiol or noethisterone and their pharmaceutically acceptable salts or a combination thereof, testosterone or progesterone. Preferred bronchodilators include salbutamol and salts thereof, bambuterol, salmeterol xinafoate, fluticasone propionate, mometasone furoate, budesonide, beclomethasone dipropionate, sodium cromoglycate and isoprenaline sulphate. Preferred drugs used in case of osteoporosis include alendronic acid, pamidronic acid, etidronic acid and their pharmaceutically acceptable salts. Preferred drugs used to treat incontinence include vasopressin and oxybutynin. Preferred antidepressants/anxiolytics include imipramine, mirtazapine and desipramine. Preferred antimigraine agents include naratriptan, zolmitriptan and sumatriptan. One preferred antidiarrheal is loperamide. One preferred antiulcerant is misoprostol. Preferred anticholinergics include hyoscyamine, atropine and trihexyphenidyl. Preferred anticonvulsants include lorazepam, diazepam and tiagabine. Preferred drugs for antimood disorders/obsessive compulsive disorder include fluoxetine and paroxetine. Preferred ACE inhibitors include lisinopril, trandolapril and captopril. Preferred calcium channel blockers include amlodipine and felodipine. Preferred antihypertensives/diuretics include prazosin and amiloride. Preferred antiobesity drugs include methamphetamine and sibutramine hydrochloride. Preferred hormonal peptides and analogues include GnRH analogues such as nafarelin, leuprolide acetate, insulin and growth hormone and analogues thereof. Preferred drugs for benign prostatic hyperplasia/urinary retention include doxazosin, tamsulosin, terazosin and finasteride. Preferred drugs for erectile dysfunction include alprostadil and sildenafil citrate. Preferred antiparkinson agents include dopamine agonists such as bromocriptine and cabergoline and MAO inhibitors such as selegiline HCl. One preferred agent for sleep disorders is melatonin. Preferred antidiabetic agents include first and second generation sulphonyl ureas such as glimepiride, rosiglitazone, glyburide and glipizide. The chiral forms of all the drugs mentioned above, as well as achiral forms, can be used to make the topical spray composition of the present invention. [0029]
  • The film-formers preferably include acrylic polymers or copolymers, including methacrylic polymers and copolymers. Preferred film-formers include a non-ionic copolymer of methyl methacrylate and butyl methacrylate (Plastoid B®), a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®), ammonio methacrylate copolymer type B (Eudragit RS®, USP/NF), ammonio methacrylate copolymer type A (Eudragit RL®, USP/NF), methacrylic acid copolymer type A (Eudragit L100®, USP/NF), methacrylic acid copolymer type B (Eudragit S100® USP/NF), polyvinyl acetate, cellulose acetate, polyvinyl alcohol, povidone, povidone vinyl acetate, hydroxypropyl methyl cellulose, hydroxy ethyl cellulose, methyl cellulose and ethyl cellulose. [0030]
  • The breathability of the film is achieved by the absence of any occlusive backing membrane together with the generally hydrophilic properties of the film-forming polymer(s). These polymers can partially dissolve on exposure to moisture (from the skin or air), the dissolution resulting in the formation of a porous film. This porosity can be enhanced by including additional water-soluble additives, such as those detailed below. [0031]
  • Preferred solubilizers include a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®, USP/NF); surfactants, for example, sodium lauryl sulphate; polyhydric alcohols, for example, propylene glycol or polyethylene glycol; vitamin E, vitamin E TPGS (tocopheryl polyethylene glycol 1000 succinate) and labrasol; or any two or more of the above in combination. Preferably, the solubilizer is a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester (Eudragit E100®) in combination with, a non-ionic copolymer of methyl methacrylate and butyl methacrylate (Plastoid B®). The solubilizers serve to dissolve the drug in the chosen vehicle. Many of the solubilizers also enhance percutaneous penetration of drug and/or act as humectants. [0032]
  • Preferred plasticizers include triethyl citrate, dimethyl isosorbide, acetyltributyl citrate, castor oil, propylene glycol, and polyethylene glycol, or any two or more of the above in combination. [0033]
  • The permeation enhancer is preferably a lipophilic solvent, for example, dimethyl sulfoxide, dimethyl formamide or isopropyl myristate; a surfactant, for example, Tweens or sodium lauryl sulfate; menthol; oleic acid, octyl dimethyl para-amino benzoic acid (Padimate 0); mixed esters of capric and caprylic acid; or a polyhydric alcohol, for example, propylene glycol or diethylene glycol monoethyl ether EP (transcutol); or any two or more of the above in combination. [0034]
  • The vehicle can be water or a non-aqueous solvent. Preferred nonaqueous vehicles include acetone, isopropyl alcohol, methylene chloride, methyl-ethyl-ketone, absolute alcohol, ethyl acetate and trichloromonofluoromethane (P11), methylene dimethyl ether or any two or more of the above in combination. [0035]
  • The aqueous or non-aqueous vehicle may additionally comprise (weight/weight of vehicle) up to 20% of one or more humectants. Preferred humectants include polyhydric alcohols and polyvinyl pyrrolidone. Preferred polyhydric alcohols are propylene glycol, butylene glycol, polyethylene glycol, glycerol and sorbitol. [0036]
  • The water-soluble additive is preferably propylene glycol, sodium lauryl sulphate, one or more polaxomers, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, cetomacrogol, polyethylene glycol or transcutol, or any two or more of the above in combination. [0037]
  • When the composition is dispensed as an aerosol, the vehicle partly comprises a propellant in an amount to provide from about 10% to about 90% (w/w) of the composition. The propellant can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure of from about 20 p.s.i.g. to about 130 p.s.i.g. Preferred propellants include hydrocarbons, for example, propane, butane, isobutane, or dimethylether; hydrofluorocarbons and hydrochlorofluorocarbons, for example, dichlorodifluoromethane (P12), trichloromonofluoromethane (P11), dichlorofluoroethane, monochlorodifluoromethane (P22), dichlorotetrafluoroethane (P114), difluoroethane (P152a), tetrafluoroethane (134a), heptafluoropropane (P227b); or compressed gases, for example, nitrogen or carbon dioxide. [0038]
  • The topical compositions of the present invention are quick drying, non-occlusive formulations which cause marked enhancement of the skin permeation of the drug both in vitro and in vivo when compared with existing transdermal patches. They offer the advantages of lower skin irritation, greater ease of use, increased dosage flexibility and a simpler method of manufacture when compared to existing transdermal patches. [0039]
  • The present compositions are a significant advance over conventional medicinal aerosol compositions, since they permit the application of a medicament by a method whereby no physical contact on the area of application is required, except by the film-forming spray itself. The topical films formed by the present compositions show excellent stability and peelability and can be easily removed from the site of application by washing with water. [0040]
  • The compositions are generally prepared by mixing the ingredients, without liquefied propellant, at a temperature of from 0° C. to 100° C. and at ambient pressure. If propellant is to be added, the resulting mixture is then charged with the liquefied propellant into an aerosol dispenser to achieve the final composition. Mixing is preferably carried out at a temperature of from 10° C. to 25° C. Alternatively, the mixed composition is placed in a pump dispenser, for example, a metered dose pump, which dispenses the composition typically without liquefied propellant since a pressurized atmosphere is not required. Propellant which is liquid at room temperature may, however, be included in a pump dispenser composition as part of the aqueous vehicle. The composition so prepared is sprayed from the dispenser onto a topical site, at which site it forms a stable, plastic film or patch. [0041]
  • The aerosol dispenser is preferably a conventional aerosol can having a conventional metered spray aerosol valve. The pump dispenser is preferably a conventional can or bottle having a conventional metered spray pump. Preferably, the aerosol dispenser has an all position valve having a shroud that permits spraying when the dispenser is held at any angle. In this way, horizontal bottom surfaces, as well as horizontal top surfaces and vertical surfaces, can be sprayed. The valve actuator can be any actuator which produces a spray and not a foam at the nozzle. A preferred valve actuator is a mechanical breakup actuator, which employs mechanical forces rather than expansion and evaporation of the propellant to produce a spray. A typical mechanical breakup actuator has a conical or cylindrical swirl chamber with an inlet channel oriented perpendicular to the axis thereof. This structure imparts a swirling motion to the aerosol mixture upon discharge. The swirling motion occurs around the axis of the swirl chamber forming a thin conical film of discharged mixture, which breaks into droplets as it leaves the swirl chamber and travels in the direction of the axis thereof. The result is a fine, soft, dispersed spray which can be easily controlled to produce a stable thin film of even thickness completely contacting the application site. In dispensing a composition of the invention, the dispenser is typically held about 1 to 2 inches (2.5 to 5 cm) from the application site and produces a film of even thickness. The dispensers used in the present invention are preferably compact units. They can be conveniently used for quick and easy application of a medicament over a large surface area. [0042]
  • The composition is preferably applied over a fixed surface area. Typically, the fixed surface area is not more than 50 cm[0043] 2, and is more preferably from 10 cm2 to 25 cm2.
  • In general, a composition according to the present invention suitable for use in an aerosol dispenser can be prepared as follows: [0044]
  • 1. Dissolve the film former in the chosen vehicle with stirring to form a clear solution; [0045]
  • 2. Dissolve or suspend the active ingredient and solubilizer(s) along with the permeation enhancer, together with any water-soluble additives required, in the solution formed in step 1; [0046]
  • 3. Add the plasticizer to the solution and fill a conventional aerosol can with the mixture; and [0047]
  • 4. Charge the filled can with liquefied propellant. [0048]
  • The following examples illustrate the preparation of compositions according to the present invention. [0049]
  • Examples 1 and 2 below represent partly generalized formulas which can be used with any suitable medicament to prepare compositions according to the present invention for use in an aerosol dispenser. [0050]
    • EXAMPLE 1
  • [0051]
    Ingredients Percent w/w
    Active ingredient 0.5-10.0
    Plastoid B 2.25
    Eudragit E 100 0.25
    Propylene glycol 3.0
    Sodium lauryl sulfate 3.5
    Acetone 20
    Propellant q.s.
    Vitamin E 0.1
    Transcutol 1.0
    • EXAMPLE 2
  • [0052]
    Ingredients Percent w/w
    Active ingredient 15
    Povidone 3
    Povidone VA-64 2
    Vitamin E 0.5
    PEG 400 1.0
    Propylene glycol 1.5
    Ethanol 15
    Acetone 15
    Propellant q.s.
  • More specific examples of compositions for use in an aerosol dispenser are set forth in Examples 3 through 5. [0053]
    • EXAMPLE 3
  • [0054]
    Ingredients Percent w/w
    Estradiol 1
    PVP-K-30 6
    PVP VA 4
    Vitamin E 1
    PEG 6000 2
    Propylene glycol 3
    P 12 58.1
    P 11 24.9
    • EXAMPLE 4
  • [0055]
    Ingredients Percent w/w
    Estradiol 2
    PVP K-30 6
    PVP VA 4
    Vitamin E 1
    PEG 6000 2
    Propylene glycol 3
    P 12 24.9
    P 11 57.1
    • EXAMPLE 5
  • [0056]
    Ingredients Percent w/w
    Alendronate sodium 1
    PVP K-30 6
    PVP VA 4
    Vitamin E 0.5
    Menthol 0.05
    Dimethyl isosorbide 3.0
    Acetone 10
    Ethanol 10
    Tetrafluoroethane (P134) 25.45
    Dichlorodifluoromethane 40
    (P12)
  • To prepare a composition according to the present invention suitable for use in a pump dispenser, the general method set forth above for an aerosol dispenser can be used, except that it is not necessary to charge the pump dispenser with liquefied propellant to provide a pressurized atmosphere. The mixture itself may contain propellant which is liquid at room temperature as part of the vehicle. [0057]
  • Examples 6 through 9 represent partly generalized formulas which can be used with any suitable medicament to prepare compositions according to the present invention for use in a pump dispenser. [0058]
    • EXAMPLE 6
  • [0059]
    Ingredients Percent w/w
    Active ingredient 0.5-10.0
    Plastoid B 5.6
    Eudragit E 100 0.6
    Propylene glycol 4.0
    Sodium lauryl sulfate 3.0
    Acetone 20
    Isopropyl alcohol q.s.
    Vitamin E 0.2
    Transcutol 2.0
    • EXAMPLE 7
  • [0060]
    Ingredients Percent w/w
    Active ingredient 25
    Povidone 6
    Povidone VA-64 4
    Vitamin-E 1.0
    Propylene glycol 3
    Ethanol 27
    Acetone q.s.
    Methylene chloride 27
    • EXAMPLE 8
  • [0061]
    Ingredients Percent w/w
    Active ingredient 15
    PVP K 30 6
    PVP VA 4
    Vitamin-E TPGS 0.5
    Dimethyl isosorbide 5
    Ethanol 20
    Trichloromonofluoromethane q.s.
    (P11)
    • EXAMPLE 9
  • [0062]
    Ingredients Percent w/w
    Active ingredient 0.5-10
    PVP VA 10
    Vitamin E 0.5
    Propylene glycol 3
    Ethanol 25
    Trichloromonofluoromethane q.s.
    (P11)
  • More specific examples of compositions which can be used in a pump dispenser are set forth in Examples 10 through 12. [0063]
    • EXAMPLE 10
  • [0064]
    Ingredients Percent w/w
    Estradiol 2
    PVP K-30 6
    PVP VA 4
    Vitamin E 1
    PEG 6000 2
    Propylene glycol 3
    Acetone 27
    Methylene chloride 27
    Ethanol 28
    Dichlorodifluoromethane 40
    (P12)
    • EXAMPLE 11
  • [0065]
    Ingredients Percent w/w
    Estradiol 1
    PVP K-30 6
    PVP VA 4
    Vitamin E 1
    PEG 6000 2
    Polyethylene glycol 3
    Acetone 27
    Methylene chloride 28
    Ethanol 28
    • EXAMPLE 12
  • [0066]
    Ingredients Percent w/w
    Estradiol 1
    PVP K-30 6
    PVP VA 4
    Vitamin E 1
    Menthol 0.05
    Dimethyl Isosorbide 5
    Acetone 27.48
    Ethanol 27.48
    P11 27.48
  • The following further explanation is given of the above examples. Eudragit E 100 is a self-adhesive, hydrophilic matrix system. It also acts as a solubilizer for the drug Estradiol. Plastoid B is a film-former. When used together, Eudragit E 100 and Plastoid B give better peelability and water washability than when either is used alone. Acetone is a volatile, quick-drying, non-occlusive vehicle which helps to dispense the contents of the spray over a large surface area. Propylene glycol acts as a humectant to prevent the excessive drying of the application site after application of the medicament. It also acts as a plasticizer for the film formed after application. Propylene glycol additionally acts as a solubilizer for the drug and a permeation enhancer. Sodium lauryl sulfate acts as a solubilizer for the drug [0067]
  • Propellant is necessary for developing proper pressure within an aerosol container and for expulsion of the composition when the valve is open. It is also responsible, together with the valve, for dispensing the product as a fine spray. The preferred propellants are very stable compounds and relatively non-toxic, inert and non-flammable. [0068]
  • The compositions in the above examples were discharged from the dispenser as a fine, soft dispersed spray which could be easily controlled to produce a stable thin film of even thickness on a target surface, for example, a laboratory cover glass. The films have been observed to last for at least 24 hours. The concentrations of the film-formers in the composition can be varied as required to obtain a patch which can deliver the drug in a sustained manner for a period of up to 1 to 5 days. The film is easily removable from the application site by water in preparation for reapplication of the film or other treatment. [0069]
  • The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. The above-described embodiments of the invention may be modified or varied, and elements added or omitted, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described. [0070]

Claims (64)

1. A sprayable composition for topical application, comprising:
from about 0.0001% to about 30% of at least one medicament for systemic or topical availability,
at least one film former,
at least one vehicle; and at least one component selected from the group
at least one permeation enhancer:
at least one solubilizer:
at least one plasticizer; and
at least one water soluble additive
the composition forming a stable, breathable film upon application to a surface.
2. The composition according to claim 1, comprising from about 0.0001% to about 10% of the at least one medicament.
3. The composition according to claim 1, comprising from about 0.0001% to about 5% of the at least one medicament.
4. The composition according to claim 1, wherein the film former comprises from about 0.0001% to about 10% of the composition.
5. (Canceled)
6. The composition according to claim 1, comprising at least one permeation enhancer in an amount of from about 0.0001% to about 8% of the composition.
7. (Canceled)
8. The composition according to claim 1, comprising at least one solubilizer in an amount of from about 0.0001% to about 10% of the composition.
9. (Canceled)
10. The composition according to claim 1, comprising at least one plasticizer in an amount of from about 0.0001% to about 10% of the composition.
11. The composition according to claim 1, the composition comprising at least one water soluble additive in an amount of from about 0.0001% to about 7%.
12. The composition according to claim 1, wherein the at least one medicament is locally or transdermally available.
13. (Canceled)
14. The composition according to claim 1, wherein the composition comprises at least one medicament which is released from the composition immediately upon application to a biological surface.
15. The composition according to claim 1, wherein the composition comprises at least one medicament which is released from the composition over an extended period of time after application to a biological surface.
16. (Canceled)
17. The composition according to claim 1, wherein the at least one medicament is selected from the group consisting of anti-emetics, anti-anginals, anti-inflammatory agents, steroids, steroid hormones, bronchodilators, drugs used to treat osteoporosis, drugs used to treat incontinence, antidepressants/anxiolytics, antimigraine agents, agents used in smoking cessation therapy, antidiarrheals, antiulcerants, anticholinerginics, anticonvulsants, drugs for mood disorders/obsessive compulsive disorder, ACE inhibitors, calcium channel blockers, antihypertensives/diuretics, antiobesity drugs, hormonal peptides and analogues, drugs for benign prostatic hyperplasia/urinary retention and erectile dysfunctions, antiparkinson agents such as dopamine agonists and MAO inhibitors, drugs for sleep disorders and antidiabetic agents.
18. The composition according to claim 1, wherein the at least one medicament is selected from the group consisting of scopolamine, nitroglycerine, clonidine isosorbide dinitrate, propanolol hydrochloride, timolol maleate, clonazepam, verapamil, diclofenac sodium, naproxen sodium, ibuprofen, ketoprofen, indomethacin, piroxicam, ketorolac, tromethamine, nimesulide, hydrocortisone and esters thereof, dexamethasone, fluocinolone acetonide and betamethasone and salts thereof, estradiol and norethisterone or their pharmaceutically acceptable salts and combinations thereof, testosterone, progesterone, salbutamol and salts thereof, bambuterol, salmeterol xinafoate, fluticasone propionate, mometasone furoate, budesonide, beclomethasone dipropionate, sodium cromoglycate or isoprenaline sulphate, alendronic acid, pamidronic acid, etidronic acid or salts thereof, vasopressin, oxybutynin, imipramine, mitrazapine, desipramine, naratriptan, zolmitriptan, sumatriptan, nicotine, loperamide, misoprostol, hyoscyamine, atropine, trihexyphenidyl, lorazepam, diazepam, tiagabine, fluoxetine, paroxetine, lisinopril, trandolapril, captopril, amlodipine, felodipine, prazosin, amiloride, methamphetamine, sibutramine hydrochloride, nafarelin, leuprolide acetate, insulin, growth hormone and analogues thereof, doxazosin, tamsulosin, terazosin, finasteride, alprostadil, sildenafil citrate, bromocriptine, cabergoline, selegiline, melatonin, glimepiride, rosiglitazone, glyburide, glipizide and combinations thereof.
19. The composition according to claim 1, wherein the at least one medicament is present as a single enantiomer.
20. The composition according to claim 6, wherein the at least one permeation enhancer is selected from the group consisting of lipophilic solvents, surfactants, oleic acid, octyl dimethyl benzoic acid, menthol, mixed esters of capric and caprylic acid, polyhydric alcohols, dimethyl sulfoxide, dimethyl formamide, isopropyl myristate, Tween, sodium lauryl sulfate, propylene glycol, transcutol and combinations thereof.
21. (Canceled)
22. The composition according to claim 1, wherein the at least one vehicle comprises water, at least one non-aqueous solvent, or at least one propellant.
23. The composition according to claim 22, wherein the at least one non-aqueous solvent is selected from the group consisting of acetone, isopropyl alcohol, methylene chloride, methyl ethyl ketone, absolute alcohol, ethyl acetate trichloromonofluoroethane (P11) and methylene dimethyl ether.
24. (Canceled)
25. The composition according to claim 22, wherein the at least one propellant comprises from about 10% to about 90% of the composition.
26. The composition according to claim 22, wherein the at least one propellant is selected from the group consisting of a hydrocarbon, a hydrofluorocarbon, hydrochlorofluorocarbon, a compressed gas propane, butane, isobutane, dimethylether, dichlorodifluoromethane (P12), trichloromonofluoromethane (P11) dichlorofluoroethane, monochlorodifluoromethane (P22), dichlorotetrafluoroethane (P114), difluoroethane (P152A). tetrafluoroethane (P134A), heptafluoropropane (P227B), nitrogen and carbon dioxide.
27. (Canceled)
28. The composition according to claim 1, wherein the at least one vehicle comprises from about 1% to about 20% (w/w) of at least one humectant.
29. The composition according to claim 28, wherein the at least one humectant is selected from the group consisting of polyhydric alcohols polyvinyl pyrrolidone, propylene glycol, butylene glycol, a polyethylene glycol, glycerol and sorbitol.
30. (Canceled)
31. The composition according to claim 1, wherein the at least one film-former is selected from the group consisting of acrylic polymers or copolymers, polyvinyl acetate, cellulose acetate, polyvinyl alcohol, povidone, copolypovidone povidone vinyl acetate, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl cellulose and ethyl cellulose.
32. The composition according to claim 31, wherein the acrylic polymer or copolymer is selected from the group consisting of non-ionic copolymers of methyl methacrylate and butyl methacrylate, copolymers of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester, ammonio methacrylate copolymer type B, ammonio methacrylate copolymer type A, methacrylic acid copolymer type A and methacrylic acid copolymer type B.
33. The composition according claim 8, wherein the at least one solubilizer is selected from the group consisting of copolymers of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester, a surfactant, a polyhydric alcohol, vitamin E, vitamin E TPGS (tocopheryl polyethylene 1000 succinate), labrasol, propylene carbonate, sodium laurel sulphate, Tweens, spans, propylene glycol polyethylene glycol and combinations thereof.
34. (Canceled)
35. The composition according to claim 10, wherein the at least one plasticizer is selected from the group consisting of triethyl citrate, dimethyl isosorbide, acetyltributyl citrate, castor oil, propylene glycol, polyethylene glycol, and combinations thereof.
36. The composition according to claim 11, wherein the at least one water soluble additive is selected from the group consisting of propylene glycol, sodium lauryl sulfate, one or more polaxomers, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, cetomacrogol, polyethylene glycol, diethylene glycol, monoethyl ether EP (transcutol), and combinations thereof.
37. The composition according to claim 1, comprising:
from about 0.0001% to about 30% of at least one medicament for topical or systemic availability,
at least one film-former,
at least one solubilizer,
at least one permeation enhancer,
at least one plasticizer, and
at least one vehicle
said composition forming a stable, breathable film upon application to a surface.
38. The composition according to claim 37, wherein the at least one medicament comprises from about 0.0001% to about 10% of the composition.
39. The composition according to claim 37, wherein the at least one medicament comprises from about 0.0001% to about 5% of the composition.
40. The composition according to claim 37, wherein the at least one film former comprises from about 0.0001% to about 10% of the composition, the at least one solubilizer comprises from about 0.0001% to about 10% of the composition, the at least one permeation enhancer comprises from about 0.0001% to about 8% of the composition, and the at least one plasticizer comprises from about 0.0001% to about 10% of the compositi.
41-43. (Canceled)
44. The composition according to claim 37, further comprising from about 0.0001% to about 7% of at least one water soluble additive.
45. The composition according to claim 37, wherein the film-former is a non-ionic copolymer of methyl methacrylate and butyl methacrylate and the solubilizer is a copolymer of dimethylamine ethyl methacrylate and a neutral methacrylic acid ester.
46. A stable, breathable film formed on the skin by topically applying a composition to an intended application site, said composition comprising
from about 0.001% to about 30% of at least one medicament for topical or systemic availability,
at least one film-former;
at least one vehicle; and at least one component selected from the group
at least one permeation enhancer;
at least one solubilizer;
at least one plasticizer, and
at least one water soluble additive.
47. The film according to claim 46, wherein the composition comprises up to about 10% of the at least one medicament.
48. The film according to claim 46, wherein the composition comprises up to about 5% of the at least one medicament.
49-51. (Canceled)
52. The film according to claim 46, wherein the film is formed over a fixed surface area.
53. The film according to claim 52, wherein the fixed surface area is less than about 50cm2.
54. The film according to claim 52, wherein the fixed surface area is from about 10 cm2 to about 25 cm2.
55. The film according to claim 46, wherein the at least one medicament is locally or transdermally available.
56. A stable, breathable film formed on the skin by topically applying a composition according to claim 37.
57. A method of using at least one medicament, comprising the steps of:
providing a composition for topical application, and
dispensing a metered dose of said composition onto an intended application site on the skin;
wherein the composition comprises from about 0.0001% to about 30% of at least one medicament for systemic or topical availability,
at least one film former,
at least one vehicle; and at least one component selected from the group
at least one permeation enhancer;
at least one solubilizer;
at least one plasticizer; and
at least one water soluble additive.
58. The method according to claim 57, wherein the composition comprises up to about 10% of the at least one medicament.
59. The method according to claim 57, wherein the composition comprises up to about 5% of the at least one medicament.
60. The method according to claim 57, wherein the at least one film former comprises from about 0.0001% to about 10% of the composition.
61-66. (Canceled)
67. The method according to claim 57, wherein the metered dose is dispensed over a fixed surface area.
68. The method according to claim 67, wherein the fixed surface area is not more than about 50 cm2.
69. The method according to claim 68, wherein the fixed surface area is from about 10 cm2 to about 25 cm2.
70. The method according to claim 57, wherein said dispensing comprises spraying.
71. The method according to claim 57, wherein the composition forms a stable, breathable film after dispensing on the application site.
72. The method of claim 70, wherein said dispensing is conducted by an apparatus selected from the group consisting of a pump dispenser and an aerosol dispenser.
73. (Canceled)
US10/686,517 1999-05-20 2003-10-16 Topical spray compositions Abandoned US20040213744A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/686,517 US20040213744A1 (en) 1999-05-20 2003-10-16 Topical spray compositions

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN382BO1999 1999-05-20
IN582BO1999 1999-08-17
IN582/BOM/2000 1999-08-17
IN44BO2000 2000-01-13
IN43/BOM/2000 2000-01-13
IN382/BOM/99 2000-01-13
IN44/BOM/2000 2000-01-13
IN43BO2000 2000-01-13
US09/503,843 US6962691B1 (en) 1999-05-20 2000-02-15 Topical spray compositions
US10/686,517 US20040213744A1 (en) 1999-05-20 2003-10-16 Topical spray compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/503,843 Continuation US6962691B1 (en) 1999-05-20 2000-02-15 Topical spray compositions

Publications (1)

Publication Number Publication Date
US20040213744A1 true US20040213744A1 (en) 2004-10-28

Family

ID=35206939

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/503,843 Expired - Fee Related US6962691B1 (en) 1999-05-20 2000-02-15 Topical spray compositions
US10/686,517 Abandoned US20040213744A1 (en) 1999-05-20 2003-10-16 Topical spray compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/503,843 Expired - Fee Related US6962691B1 (en) 1999-05-20 2000-02-15 Topical spray compositions

Country Status (1)

Country Link
US (2) US6962691B1 (en)

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005041943A1 (en) * 2003-10-23 2005-05-12 Cipla Limited Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle
US20050287194A1 (en) * 2004-05-07 2005-12-29 Arnaud Grenier Permeation enhancing compositions for anticholinergic agents
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
WO2007031753A2 (en) * 2005-09-14 2007-03-22 Medpharm Limited Topical film-forming monophasic formulations
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US20080319092A1 (en) * 2005-08-05 2008-12-25 Nuvo Research Inc. Transdermal Drug Delivery Formulation
US7470433B2 (en) * 2000-08-03 2008-12-30 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20090048296A1 (en) * 2007-08-17 2009-02-19 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
US20090215888A1 (en) * 2006-03-02 2009-08-27 Singh Jagat Topical nail formulation
WO2009110009A3 (en) * 2008-03-07 2009-12-23 Sun Pharma Advanced Research Company Ltd., Opthalmic composition
US20100210702A1 (en) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc. Anti-fungal formulation
CN102018671A (en) * 2011-01-05 2011-04-20 浙江大学 Estradiol transdermal spray and preparation method thereof
US20110212201A1 (en) * 2010-03-01 2011-09-01 Jatinder Rana Skin Whitening Composition Containing Chia Seed Extract
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2011154004A1 (en) * 2010-06-11 2011-12-15 Leo Pharma A/S A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US8119694B2 (en) 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
US8268346B2 (en) 2006-04-21 2012-09-18 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20130005816A1 (en) * 2011-05-03 2013-01-03 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US20130189427A1 (en) * 2012-01-25 2013-07-25 Illionis Tool Works, Inc. Vehicle wheel and hub protectant film and composition for the formation thereof
CN103319390A (en) * 2013-07-10 2013-09-25 山西普德药业股份有限公司 Alprostadil compound and composition thereof
WO2014006201A1 (en) * 2012-07-06 2014-01-09 Leo Pharma A/S A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8980309B2 (en) 2003-10-10 2015-03-17 Antares Pharma Ipl Ag Transdermal testosterone formulation for minimizing skin residues
US9066913B2 (en) 2006-10-17 2015-06-30 Hznp Limited Diclofenac topical formulation
US9084723B2 (en) 2001-05-01 2015-07-21 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions with an erodible backing member
US9089481B2 (en) 2001-05-01 2015-07-28 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions demonstrating phase separation on contact with aqueous media
US9127140B2 (en) 2001-05-01 2015-09-08 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Water-absorbent adhesive compositions and associated methods of manufacture and use
US9132110B2 (en) 2009-03-31 2015-09-15 Hznp Limited Treatment of pain with topical diclofenac
US20150258169A1 (en) * 2012-06-26 2015-09-17 Biofunctional Structure Research Institute, Bfsr Co. Ltd. Topical preventative medicament against burns-related systemic inflammatory response syndrome
US9144552B2 (en) 2004-01-30 2015-09-29 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Rapidly dissolving film for delivery of an active agent
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9259504B2 (en) 2001-05-01 2016-02-16 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Non-electrically conductive hydrogel composition
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2016065341A1 (en) * 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
CN105853357A (en) * 2016-04-26 2016-08-17 中国药科大学 Multifunctional cooperative mixed micelle drug delivery system and preparation method thereof
WO2016161397A1 (en) * 2015-04-03 2016-10-06 Insys Development Company, Inc. Sildenafil sublingual spray formulations
US9532935B2 (en) 2001-05-01 2017-01-03 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US9610253B2 (en) 2009-01-14 2017-04-04 Corium International, Inc. Transdermal administration of tamsulosin
US9616023B2 (en) 2011-02-25 2017-04-11 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
US9675552B2 (en) 2012-05-31 2017-06-13 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
US9693983B2 (en) 2010-08-03 2017-07-04 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018116190A1 (en) * 2016-12-21 2018-06-28 Dr. Reddy's Laboratories Limited Topical sprayable compositions of ketorolac tromethamine
US10034850B2 (en) 2013-11-29 2018-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
CN109069390A (en) * 2016-04-11 2018-12-21 苏文生命科学有限公司 The external application spray formulation of glycopyrronium bromide
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10383854B2 (en) 2011-09-12 2019-08-20 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2020010205A1 (en) * 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN112353785A (en) * 2019-07-26 2021-02-12 纵曜光 Spray type film medicinal plaster
US11044937B2 (en) 2014-11-07 2021-06-29 Nicoventures Trading Limited Solution comprising nicotine in unprotonated form and protonated form
US11166931B2 (en) 2012-05-31 2021-11-09 G. Pohl-Boskamp Gmbh & Co. Kg Induction of arteriogenesis with an NO (nitric oxide) donor
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11827899B2 (en) 2015-12-30 2023-11-28 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
DE60239528D1 (en) 2001-05-01 2011-05-05 Corium International Redwood City TWO-PHASE, WATER-ABSORBING BIOADHESIVE COMPOSITION
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196323A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189980A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070189977A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Spray-on formulations and methods for dermal delivery of drugs
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
JP5270158B2 (en) 2004-08-05 2013-08-21 コリウム インターナショナル， インコーポレイテッド Adhesive composition
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
WO2007079466A2 (en) * 2006-01-04 2007-07-12 Nano Mist International, Llc Air driven delivery system for sprayable media
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
WO2009120933A2 (en) 2008-03-28 2009-10-01 Particle Sciences, Inc. Pharmaceutical solutions and method for solubilizing therapeutic agents
CN101658487B (en) * 2008-08-28 2011-10-05 北京天川军威医药技术开发有限公司 Glimepiride aqueous solution administration system and preparation method thereof
US20100068278A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Ex vivo modifiable medicament release-associations
ES2637447T3 (en) 2009-08-31 2017-10-13 Dr. Reddy's Laboratories Ltd. Topical formulations containing a steroid
KR101955175B1 (en) 2010-04-13 2019-03-06 나지브 바불 Dermal pharmaceutical compositions of 1-methyl-2'-6'-pipecoloxylidide and method of use
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US10149828B2 (en) 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
WO2019140087A1 (en) 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
WO2020161771A1 (en) * 2019-02-04 2020-08-13 マルホ株式会社 Skin composition
CN114668762A (en) * 2020-12-24 2022-06-28 江苏恒瑞医药股份有限公司 A pharmaceutical composition
WO2024028896A1 (en) * 2022-08-01 2024-02-08 Pontika Aerotech Ltd A topical spray based on beta caryophylene for the management of pain and inflammation

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476853A (en) * 1965-04-13 1969-11-04 Colgate Palmolive Co Sprayed opaque bandage composition
US3932602A (en) * 1972-11-21 1976-01-13 Novitas Nuprot Sa Non-stinging wound dressing
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4293542A (en) * 1976-05-03 1981-10-06 L'oreal Cosmetic composition for imparting to human skin a coloration resembling a natural tan
US4316887A (en) * 1977-11-07 1982-02-23 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for topical application and method for preparing the same
US4328319A (en) * 1980-10-27 1982-05-04 Restech Research Limited Partnership Process for preparing propellant compositions forming foamed structures containing open and/or closed cells
US4534958A (en) * 1983-07-13 1985-08-13 Basf Wyandotte Corporation Aerosol gel
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5248494A (en) * 1992-06-10 1993-09-28 Young Pharmaceuticals Inc. Method of reducing anthralin induced inflammation and staining
US5413792A (en) * 1989-03-31 1995-05-09 Dow Corning K.K. Mucoadhesive polysiloxane paste-like base and preparation
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US5980921A (en) * 1995-11-06 1999-11-09 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1372721A (en) 1971-01-16 1974-11-06 Wilkinson Sword Ltd Containers of antiseptics for the treatment of burns and scalds
DE3045914A1 (en) 1980-12-05 1982-07-22 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF ELASTIC LIQUID PLASTERS
DE3045915A1 (en) 1980-12-05 1982-07-08 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF ELASTIC LIQUID PLASTERS
DE3612305A1 (en) 1986-04-11 1987-10-22 Roehm Pharma Gmbh LIQUID MEDICINE FOR THERAPY OF PSORIASIS BASED ON FILM-FORMING POLYMERS
WO1988009185A1 (en) 1987-05-27 1988-12-01 Kurt Burghart Transdermal therapeutically effective pharmaceutical dressing and device for applying it
DE68910230T2 (en) 1988-08-24 1994-03-03 Dento Med Ind Inc Cosmetic preparation.
TW247878B (en) 1991-07-02 1995-05-21 Takeda Pharm Industry Co Ltd
DE4310012A1 (en) 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture
CA2159498A1 (en) 1993-04-01 1994-10-13 Younsik Cha Method for preparing drugs to treat dermal disorders
GB9408545D0 (en) 1994-04-29 1994-06-22 Zyma Sa Compositions
US5607686A (en) 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
FR2732223B1 (en) 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US6060547A (en) * 1995-04-28 2000-05-09 The Proctor & Gamble Company Film forming foundation
PT804151E (en) 1995-06-29 2003-01-31 Macrochem Corp COMPOSITIONS OF LIPOFILIC AND AMPHYFILIC FILM FORMULATORS AND THEIR USE IN A SYSTEM OF ADMINISTRATION OF TOPICAL AGENTS AND METHOD OF ADMINISTRATION OF SKIN AGENTS
CA2183415C (en) 1995-09-01 2000-10-10 Minh Q. Hoang A new skin preparation composition
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
CA2341220A1 (en) 1998-08-20 2000-03-02 3M Innovative Properties Company Spray on bandage and drug delivery system
US20070134259A1 (en) 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476853A (en) * 1965-04-13 1969-11-04 Colgate Palmolive Co Sprayed opaque bandage composition
US3932602A (en) * 1972-11-21 1976-01-13 Novitas Nuprot Sa Non-stinging wound dressing
US4293542A (en) * 1976-05-03 1981-10-06 L'oreal Cosmetic composition for imparting to human skin a coloration resembling a natural tan
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4316887A (en) * 1977-11-07 1982-02-23 Toko Yakuhin Kogyo Kabushiki Kaisha Composition for topical application and method for preparing the same
US4328319A (en) * 1980-10-27 1982-05-04 Restech Research Limited Partnership Process for preparing propellant compositions forming foamed structures containing open and/or closed cells
US4534958A (en) * 1983-07-13 1985-08-13 Basf Wyandotte Corporation Aerosol gel
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US5413792A (en) * 1989-03-31 1995-05-09 Dow Corning K.K. Mucoadhesive polysiloxane paste-like base and preparation
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5248494A (en) * 1992-06-10 1993-09-28 Young Pharmaceuticals Inc. Method of reducing anthralin induced inflammation and staining
US5980921A (en) * 1995-11-06 1999-11-09 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7470433B2 (en) * 2000-08-03 2008-12-30 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8652491B2 (en) 2000-08-03 2014-02-18 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US9687428B2 (en) 2001-05-01 2017-06-27 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US10835454B2 (en) 2001-05-01 2020-11-17 Corium, Inc. Hydrogel compositions with an erodible backing member
US9259504B2 (en) 2001-05-01 2016-02-16 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Non-electrically conductive hydrogel composition
US10869947B2 (en) 2001-05-01 2020-12-22 Corium, Inc. Hydrogel compositions
US9089481B2 (en) 2001-05-01 2015-07-28 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions demonstrating phase separation on contact with aqueous media
US9084723B2 (en) 2001-05-01 2015-07-21 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions with an erodible backing member
US9127140B2 (en) 2001-05-01 2015-09-08 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Water-absorbent adhesive compositions and associated methods of manufacture and use
US9532935B2 (en) 2001-05-01 2017-01-03 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US10179096B2 (en) 2001-05-01 2019-01-15 Corium International, Inc. Hydrogel compositions for tooth whitening
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US8980309B2 (en) 2003-10-10 2015-03-17 Antares Pharma Ipl Ag Transdermal testosterone formulation for minimizing skin residues
WO2005041943A1 (en) * 2003-10-23 2005-05-12 Cipla Limited Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aqueous vehicle
US20070219171A1 (en) * 2003-10-23 2007-09-20 Waterlead Limited Transdermal Pharmaceutical Spray Formulations Comprising a Vp/Va Copolymer and a Non-Aquous Vehicle
US9144552B2 (en) 2004-01-30 2015-09-29 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Rapidly dissolving film for delivery of an active agent
US20050287194A1 (en) * 2004-05-07 2005-12-29 Arnaud Grenier Permeation enhancing compositions for anticholinergic agents
US8338400B2 (en) 2005-05-27 2012-12-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
US20080319092A1 (en) * 2005-08-05 2008-12-25 Nuvo Research Inc. Transdermal Drug Delivery Formulation
US8349297B2 (en) 2005-09-14 2013-01-08 Medpharm Limited Topical formulations
CN101304730B (en) * 2005-09-14 2011-01-19 美地医药有限公司 Topical formulations
WO2007031753A2 (en) * 2005-09-14 2007-03-22 Medpharm Limited Topical film-forming monophasic formulations
WO2007031753A3 (en) * 2005-09-14 2007-06-07 Medpharm Ltd Topical film-forming monophasic formulations
AU2006290487B2 (en) * 2005-09-14 2012-06-28 Medpharm Limited Topical film-forming monophasic formulations
US20090191271A1 (en) * 2005-09-14 2009-07-30 Med Pharm Limited Topical Formulations
US20090215888A1 (en) * 2006-03-02 2009-08-27 Singh Jagat Topical nail formulation
US8647665B2 (en) 2006-04-21 2014-02-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8268346B2 (en) 2006-04-21 2012-09-18 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US9539335B2 (en) 2006-10-17 2017-01-10 Hznp Limited Diclofenac topical formulation
US9066913B2 (en) 2006-10-17 2015-06-30 Hznp Limited Diclofenac topical formulation
US9168305B2 (en) 2006-10-17 2015-10-27 Hznp Limited Diclofenac topical formulation
US9339552B2 (en) 2006-10-17 2016-05-17 Hznp Limited Diclofenac topical formulation
US9220784B2 (en) 2006-10-17 2015-12-29 Hznp Limited Diclofenac topical formulation
US9339551B2 (en) 2006-10-17 2016-05-17 Hznp Limited Diclofenac topical formulation
US9168304B2 (en) 2006-10-17 2015-10-27 Hznp Limited Diclofenac topical formulation
US9101591B2 (en) 2006-10-17 2015-08-11 Hznp Limited Diclofenac topical formulation
US20090048296A1 (en) * 2007-08-17 2009-02-19 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
WO2009110009A3 (en) * 2008-03-07 2009-12-23 Sun Pharma Advanced Research Company Ltd., Opthalmic composition
US20110003816A1 (en) * 2008-03-07 2011-01-06 Sun Pharma Advanced Research Company Limited Ophthalmic composition
US10758502B2 (en) 2008-08-15 2020-09-01 Centrexion Therapeutics Corporation High concentration local anesthetic formulations
US11517546B2 (en) 2008-08-15 2022-12-06 Centrexion Therapeutics Corporation High concentration local anesthetic formulations
US8119694B2 (en) 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
US9370500B2 (en) 2008-08-15 2016-06-21 Centrexion Therapeutics Corporation High concentration local anesthetic formulations
US9610253B2 (en) 2009-01-14 2017-04-04 Corium International, Inc. Transdermal administration of tamsulosin
US10238612B2 (en) 2009-01-14 2019-03-26 Corium International, Inc. Transdermal administration of tamsulosin
US8193232B2 (en) 2009-02-13 2012-06-05 Topica Pharmaceuticals, Inc. Anti-fungal formulation
US20100210702A1 (en) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc. Anti-fungal formulation
US20100210703A1 (en) * 2009-02-13 2010-08-19 Vontz Charles G Anti-fungal formulation
US8193233B2 (en) 2009-02-13 2012-06-05 Topica Pharmaceuticals, Inc. Anti-fungal formulation
US8362059B2 (en) 2009-02-13 2013-01-29 Topica Pharmaceuticals, Inc. Anti-fungal formulation
US9375412B2 (en) 2009-03-31 2016-06-28 Hznp Limited Treatment of pain with topical diclofenac
US9370501B2 (en) 2009-03-31 2016-06-21 Hznp Limited Treatment of pain with topical diclofenac
US9132110B2 (en) 2009-03-31 2015-09-15 Hznp Limited Treatment of pain with topical diclofenac
US9415029B2 (en) 2009-03-31 2016-08-16 Hznp Limited Treatment of pain with topical diclofenac
US10058519B2 (en) 2009-03-31 2018-08-28 Hznp Limited Treatment of pain with topical diclofenac
US8916212B2 (en) 2010-03-01 2014-12-23 Access Business Group International Llc Skin whitening composition containing chia seed extract
WO2011109139A3 (en) * 2010-03-01 2011-11-24 Access Business Group International Llc Skin whitening composition containing chia seed extract
WO2011109139A2 (en) * 2010-03-01 2011-09-09 Access Business Group International Llc Skin whitening composition containing chia seed extract
US20110212201A1 (en) * 2010-03-01 2011-09-01 Jatinder Rana Skin Whitening Composition Containing Chia Seed Extract
US8685472B2 (en) 2010-03-01 2014-04-01 Access Business Group International Llc Skin whitening composition containing chia seed extract
US10716799B2 (en) 2010-06-11 2020-07-21 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10688108B2 (en) 2010-06-11 2020-06-23 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
EP2859886A1 (en) * 2010-06-11 2015-04-15 Leo Pharma A/S A pharmaceutical spray composition
US10660908B2 (en) 2010-06-11 2020-05-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10617698B2 (en) 2010-06-11 2020-04-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US9119781B2 (en) 2010-06-11 2015-09-01 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10682364B2 (en) 2010-06-11 2020-06-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
WO2011154004A1 (en) * 2010-06-11 2011-12-15 Leo Pharma A/S A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US9566286B2 (en) 2010-06-11 2017-02-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10130640B2 (en) 2010-06-11 2018-11-20 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US9693983B2 (en) 2010-08-03 2017-07-04 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
CN102018671A (en) * 2011-01-05 2011-04-20 浙江大学 Estradiol transdermal spray and preparation method thereof
CN102018671B (en) * 2011-01-05 2012-07-25 浙江大学 Estradiol transdermal spray and preparation method thereof
US9616023B2 (en) 2011-02-25 2017-04-11 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
US11419814B2 (en) 2011-05-03 2022-08-23 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US10821071B2 (en) 2011-05-03 2020-11-03 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US20130005816A1 (en) * 2011-05-03 2013-01-03 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US9849080B2 (en) 2011-05-03 2017-12-26 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US9205041B2 (en) * 2011-05-03 2015-12-08 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
US10383854B2 (en) 2011-09-12 2019-08-20 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
US11464763B2 (en) 2011-09-12 2022-10-11 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
EP3172964B1 (en) * 2011-09-12 2020-08-26 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130189427A1 (en) * 2012-01-25 2013-07-25 Illionis Tool Works, Inc. Vehicle wheel and hub protectant film and composition for the formation thereof
US9074107B2 (en) * 2012-01-25 2015-07-07 Illinois Tool Works, Inc. Vehicle wheel and hub protectant film and composition for the formation thereof
US11166931B2 (en) 2012-05-31 2021-11-09 G. Pohl-Boskamp Gmbh & Co. Kg Induction of arteriogenesis with an NO (nitric oxide) donor
US9675552B2 (en) 2012-05-31 2017-06-13 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150258169A1 (en) * 2012-06-26 2015-09-17 Biofunctional Structure Research Institute, Bfsr Co. Ltd. Topical preventative medicament against burns-related systemic inflammatory response syndrome
US9345774B2 (en) 2012-07-06 2016-05-24 Leo Pharma A/S Topical composition comprising a film-forming polymer for delivering an active ingredient to skin
WO2014006201A1 (en) * 2012-07-06 2014-01-09 Leo Pharma A/S A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103319390A (en) * 2013-07-10 2013-09-25 山西普德药业股份有限公司 Alprostadil compound and composition thereof
CN103319390B (en) * 2013-07-10 2015-06-17 山西普德药业股份有限公司 Alprostadil compound and composition thereof
US10987332B2 (en) 2013-11-29 2021-04-27 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate
US10034850B2 (en) 2013-11-29 2018-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Sprayable aqueous composition comprising glyceryl trinitrate
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11332757B2 (en) 2014-10-24 2022-05-17 Avectas Limited Delivery across cell plasma membranes
WO2016065341A1 (en) * 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
US10612042B2 (en) 2014-10-24 2020-04-07 Avectas Limited Delivery across cell plasma membranes
US11447798B2 (en) 2014-10-24 2022-09-20 Avectas Limited Delivery across cell plasma membranes
US11044937B2 (en) 2014-11-07 2021-06-29 Nicoventures Trading Limited Solution comprising nicotine in unprotonated form and protonated form
WO2016161397A1 (en) * 2015-04-03 2016-10-06 Insys Development Company, Inc. Sildenafil sublingual spray formulations
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11827899B2 (en) 2015-12-30 2023-11-28 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN109069390A (en) * 2016-04-11 2018-12-21 苏文生命科学有限公司 The external application spray formulation of glycopyrronium bromide
CN105853357A (en) * 2016-04-26 2016-08-17 中国药科大学 Multifunctional cooperative mixed micelle drug delivery system and preparation method thereof
WO2018116190A1 (en) * 2016-12-21 2018-06-28 Dr. Reddy's Laboratories Limited Topical sprayable compositions of ketorolac tromethamine
WO2020010205A1 (en) * 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN112353785A (en) * 2019-07-26 2021-02-12 纵曜光 Spray type film medicinal plaster
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Also Published As

Publication number Publication date
US6962691B1 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
US6962691B1 (en) Topical spray compositions
EP1150661B1 (en) Topical sprays comprising a film forming composition
EP1534235B1 (en) Transdermal delivery rate control using amorphous pharmaceutical compositions
ES2160239T5 (en) PHARMACEUTICAL FILMOGENA COMPOSITION FOR TRANSDERMAL ADMINISTRATION.
US20110195114A1 (en) Transdermal delivery systems for active agents
JP5677720B2 (en) Topical preparation
US20050186141A1 (en) Transdermal aerosol compositions
US20090286867A1 (en) Compositions and methods of administering doxepin to mucosal tissue
JP2003516958A (en) Pharmaceutical gel and aerosol formulation and method for administering the formulation to skin and mucosal surfaces
KR20050071373A (en) Transdermal aerosol compositions
ES2220346T3 (en) TRANSDERMAL THERAPY OF AGONISTA-ANTAGONIST OF ESTROGEN.
ES2297183T3 (en) AEROSOL FORMULATIONS CONTAINING ESTERS OF DERIVATIVES OF 3,17-DIHIDROXI STRATRIEN FOR PULMONARY ADMINISTRATION.
WO2017178966A1 (en) Topical spray formulation of glycopyrrolate
AU2003238543B2 (en) Transdermal aerosol compositions
JPH06172159A (en) Composite powdery antibacterial agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: CIPLA LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:U & I PHARMACEUTICALS, LTD.;REEL/FRAME:025137/0831

Effective date: 20100929

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION